A new study reveals “hidden” variability in how tumor cells are affected by anticancer drugs, offering new insights on why patients with the same form of cancer can have different responses to a drug. The results highlight strategies to better evaluate drug effectiveness and inform the development of synergistic drug combinations to overcome the ability of tumors to evade treatment.